Andre J Ouellette, Age 78PO Box 7367, Newport Beach, CA 92658

6335318, Jan 1, 2002

May 10, 1999

09/309487

Michael E. Selsted - Irvine CA
Jun Yuan - Dove Canyon CA
Andre J. Ouellette - Irvine CA

The Regents of the University of California - Oakland CA

A61K 3800

514 13, 514 12, 514 14, 530300, 530324, 530326, 536 231, 4353201, 4352523

The present invention relates to an isolated cyclic peptide, theta defensin, having antimicrobial activity, and to theta defensin analogs. A theta defensin can have the amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa1-Xaa6-Xaa4-Xaa4-Xaa1-Xaa1-Xaa6-Xaa4-Xaa5 -Xaa1-Xaa3-Xaa7-Xaa5, wherein Xaa1 to Xaa8 are defined; wherein Xaa1 can be linked through a peptide bond to Xaa8; and wherein crosslinks can be formed between Xaa3 and Xaa3, between Xaa5 and Xaa5, and between Xaa7 and Xaa7. For example, the invention provides a theta defensin having the amino acid sequence Gly-Phe-Cys-Arg-Cys-Leu-Cys-Arg-Arg-Gly-Val-Cys-Arg-Cys-Ile-Cys-Thr-Arg (SEQ ID NO:1), wherein the Gly at position 1 (Gly-1) is linked through a peptide bond to Arg-18, and wherein disulfide bonds are present between Cys-3 and Cys-16, between Cys-5 and Cys-14, and between Cys-7 and Cys-12. The invention also relates to antibodies that specifically bind a theta defensin and to isolated nucleic acid molecules encoding a theta defensin. In addition, the invention relates to methods of using theta defensin or a theta defensin analog to reduce or inhibit microbial growth or survival in an environment capable of sustaining microbial growth or survival by contacting the environment with the theta defensin.

6514727, Feb 4, 2003

Sep 26, 2001

09/967808

Michael E. Selsted - Irvine CA
Jun Yuan - Dove Canyon CA
Andre J. Ouellette - Irvine CA

The Regents of the University of California - Oakland CA

C12N 1509

435 693, 4353201, 435325, 536 231, 536 237

The present invention relates to an isolated cyclic peptide, theta defensin, having antimicrobial activity, and to theta defensin analogs. A theta defensin can have the amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa1-Xaa6-Xaa4-Xaa4-Xaa1-Xaa1-Xaa6-Xaa4-Xaa5-Xaa1-Xaa3-Xaa7-Xaa5, wherein Xaa1 to Xaa8 are defined; wherein Xaa1 can be linked through a peptide bond to Xaa8; and wherein crosslinks can be formed between Xaa3 and Xaa3, between Xaa5 and Xaa5, and between Xaa7 and Xaa7. For example, the invention provides a theta defensin having the amino acid sequence Gly-Phe-Cys-Arg-Cys-Leu-Cys-Arg-Arg-Gly-Val-Cys-Arg-Cys-Ile-Cys-Thr-Arg (SEQ ID NO:1), wherein the Gly at position 1 (Gly-1) is linked through a peptide bond to Arg-18, and wherein disulfide bonds are present between Cys-3 and Cys-16, between Cys-5 and Cys-14, and between Cys-7 and Cys-12. The invention also relates to antibodies that specifically bind a theta defensin and to isolated nucleic acid molecules encoding a theta defensin. In addition, the invention relates to methods of using theta defensin or a theta defensin analog to reduce or inhibit microbial growth or survival in an environment capable of sustaining microbial growth or survival by contacting the environment with the theta defensin.

6890537, May 10, 2005

Dec 5, 2002

10/313994

Michael E. Selsted - Irvine CA, US
Jun Yuan - Dove Canyon CA, US
Andre J. Ouellette - Irvine CA, US

The Regents of the University of California - Oakland CA

A61K038/00
A61K039/00
A61K039/38

4241841, 4241851, 514 9

The present invention relates to an isolated cyclic peptide, theta defensin, having antimicrobial activity, and to theta defensin analogs. A theta defensin can have the amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa1-Xaa6-Xaa4-Xaa4-Xaa1-Xaa1-Xaa6-Xaa4-Xaa5-Xaa1-Xaa3-Xaa7-Xaa5, wherein Xaa1 to Xaa8 are defined; wherein Xaa1 can be linked through a peptide bond to Xaa8; and wherein crosslinks can be formed between Xaa3 and Xaa3, between Xaa5 and Xaa5, and between Xaa7 and Xaa7. For example, the invention provides a theta defensin having the amino acid sequence Gly-Phe-Cys-Arg-Cys-Leu-Cys-Arg-Arg-Gly-Val-Cys-Arg-Cys-Ile-Cys-Thr-Arg (SEQ ID NO:1), wherein the Gly at position 1 (Gly-1) is linked through a peptide bond to Arg-18, and wherein disulfide bonds are present between Cys-3 and Cys-16, between Cys-5 and Cys-14, and between Cys-7 and Cys-12. The invention also relates to antibodies that specifically bind a theta defensin and to isolated nucleic acid molecules encoding a theta defensin. In addition, the invention relates to methods of using theta defensin or a theta defensin analog to reduce or inhibit microbial growth or survival in an environment capable of sustaining microbial growth or survival by contacting the environment with the theta defensin.

7399823, Jul 15, 2008

May 10, 2000

10/009317

Michael E. Selsted - Irvine CA, US
Jun Yuan - Dove Canyon CA, US
Andre J. Ouellette - Irvine CA, US

The Regents of the University of California - Oakland CA

A61K 38/00

530300, 4241841, 514 2

The present invention relates to an isolated cyclic peptide, theta defensin, having antimicrobial activity, and to theta defensin analogs. A theta defensin can have the amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa1-Xaa6-Xaa4-Xaa4-Xaa1-Xaa1-Xaa6-Xaa4-Xaa5-Xaa1-Xaa3-Xaa7-Xaa8, wherein Xaa1 to Xaa8 are defined; wherein Xaa1 can be linked through a peptide bond to Xaa8; and wherein crosslinks can be formed between Xaa3 and Xaa3, between Xaa5 and Xaa5, and between Xaa7 and Xaa7. For example, the invention provides a theta defensin having the amino acid sequence Gly-Phe-Cys-Arg-Cys-Leu-Cys-Arg-Arg-Gly-Val-Cys-Arg-Cys-Ile-Cys-Thr-Arg (SEQ ID NO:1), wherein the Gly at position 1 (Gly-1) is linked through a peptide bond to Arg-18, and wherein disulfide bonds are present between Cys-3 and Cys-16, between Cys-5 and Cys-14, and between Cys-7 and Cys-12. The invention also provides nucleic acids encoding theta defensins and antibodies that specifically bind a theta defensin. In addition, the invention relates to methods of using theta defensin to reduce or inhibit microbial growth or survival.

2005026, Nov 24, 2005

May 10, 2005

11/126468

Michael Selsted - Irvine CA, US
Jun Yuan - Dove Canyon CA, US
Andre Ouellette - Irvine CA, US

The Regents of the University of California - Oakland CA

A61K038/10
C07K014/47

514013000, 514014000, 530326000

The present invention relates to an isolated cyclic peptide, theta defensin, having antimicrobial activity, and to theta defensin analogs. A theta defensin can have the amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa1-Xaa6-Xaa4-Xaa4-Xaa1-Xaa1-Xaa6-Xaa4-Xaa5-Xaa1-Xaa3-Xaa7-Xaa5, wherein Xaa1 to Xaa8 are defined; wherein Xaa1 can be linked through a peptide bond to Xaa8; and wherein crosslinks can be formed between Xaa3 and Xaa3, between Xaa5 and Xaa5, and between Xaa7 and Xaa7. For example, the invention provides a theta defensin having the amino acid sequence Gly-Phe-Cy-Arg-Cys-Leu-Cys-Arg-Arg-Gly-Val-Cys-Arg-Cys-Ile-Cys-Thr-Arg (SEQ ID NO:1), wherein the Gly at position 1 (Gly-1) is linked through a peptide bond to Arg-18, and wherein disulfide bonds are present between Cys-3 and Cys-16, between Cys-5 and Cys-14, and between Cys-7 and Cys-12. The invention also relates to antibodies that specifically bind a theta defensin and to isolated nucleic acid molecules encoding a theta defensin. In addition, the invention relates to methods of using theta defensin or a theta defensin analog to reduce or inhibit microbial growth or survival in an environment capable of sustaining microbial growth or survival by contacting the environment with the theta defensin.

5422424, Jun 6, 1995

Aug 14, 1992

7/930649

Michael E. Selsted - Irvine CA
Andre J. Ouellette - Lynn MA
Samuel I. Miller - Brookline MA

The Regents of the University of California - Oakland CA
The Shriner's Hospital for Crippled Children - Tampa FL
The General Hospital Corporation - Boston MA

C07K 710

530324

The present invention provides substantially purified cryptdin peptides having a consensus amino acid sequence as follows: X. sub. 1 -C-X. sub. 2 -C-R-X. sub. 3 -C-X. sub. 4 -E-X. sub. 5 -G-X. sub. 6 -C-X. sub. 7 -C-C-X. sub. 8 wherein X. sub. 1 is 3-6 amino acids; X. sub. 2 is one amino acid; X. sub. 3 is 2 or 3 amino acids; X. sub. 4 is three amino acids; X. sub. 5 is three amino acids; X. sub. 6 is one amino acid; X. sub. 7 is 6 to 10 amino acids; and X. sub. 8 is 0 to 7 amino acids. The invention further provides substantially purified cryptdin peptides having a consensus amino acid sequence as follows: X. sub. 1 -L-X. sub. 2 -C-Y-C-R-X. sub. 3 -C-K-X. sub. 4 -E-R-X. sub. 5 -G-T-C-X. sub. 6 -C-C-X. sub. 7 wherein X. sub.

5731149, Mar 24, 1998

Jun 7, 1995

8/486013

Michael E. Selsted - Irvine CA
Andre J. Ouellette - Lynn MA

The Shriner's Hospital For Crippled Children - Tampa FL

C12Q 168
C12P 1934
C07H 2104
C07H 2102

435 6

The present invention provides substantially purified cryptdin peptides having a consensus amino acid sequence: X. sub. 1 --C--X. sub. 2 --C--R--X. sub. 3 --C--X. sub. 4 --E--X. sub. 5 --C--X. sub. 6 --C--C--X. sub. 7 wherein X. sub. 1 is 3 to 9 amino acids; X. sub. 2 is one amino acid, preferably Y, H or R; X. sub. 3 is 2 or 3 amino acids; X. sub. 4 is three amino acids; X. sub. 5 is five amino acids; X. sub. 6 is 6 to 10 amino acids; and X. sub. 7 is 0 to 9 amino acids. The invention also provides a substantially purified mouse cryptdin having a consensus amino acid sequence: X. sub. 1 --L--X. sub. 2 --C--Y--C--R--X. sub. 3 --C--K--X. sub. 4 --E--X. sub. 5 --G--T--C--X. sub.

5844072, Dec 1, 1998

Nov 18, 1994

8/342268

Michael E. Selsted - Irvine CA
Andre J. Ouellette - Lynn MA

University of California - Alameda CA

C07K 500
C07H 2102
A01N 3718
A01N 2526

530300

The present invention provides substantially purified cryptdin peptides having a consensus amino acid sequence: X. sub. 1 -C-X. sub. 2 -C-R-X. sub. 3 -C-X. sub. 4 -E-X. sub. 5 -C-X. sub. 6 -C-C-X. sub. 7 or having a consensus amino acid sequence: X. sub. 1 -L-X. sub. 2 -C-Y-C-R-X. sub. 3 -C-K-X. sub. 4 -E-X. sub. 5 -G-T-C-X. sub. 6 -C-C-X. sub. 7 wherein X. sub. 1 to X. sub. 7 each independently is 0 to 10 amino acids. The invention also provides cryptdin analogs, which are devoid of one or more amino acids N-terminal to the first cysteine. In addition, the invention provides nucleic acid molecules encoding cryptdin peptides. The invention further provides methods for detecting inflammatory pathologies in a subject and for treating an inflammatory pathology in a subject by administering a pharmaceutical composition containing a cryptdin peptide.